REDWOOD CITY, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steven Basta, chief executive officer of Menlo Therapeutics, will present at the 2019 Cantor Global Healthcare Conference to be held in New York on October 4, 2019 at 9:30 am ET.
The presentation will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website at www.menlotherapeutics.com. A replay of the webcast will be archived on the company’s website for 30 days following the presentation.
About Menlo Therapeutics
Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus. The company’s clinical development program for serlopitant covers three indications and includes two ongoing Phase 3 clinical trials for the treatment of pruritus associated with prurigo nodularis, a Phase 3-ready clinical program for the treatment of pruritus associated with psoriasis, and a Phase 2 clinical trial for the treatment of chronic pruritus of unknown origin.
Investor Contact: email@example.com